Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E. coli Nissle 1917 for postinfectious/antibiotic-associated IBS with diarrhea
2006-000500-16Phase 3Completed
- Sponsor
- Ardeypharm
- Start
- Oct 2006
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D), Postinfectious irritable bowel syndrome (PI-IBS) and irritable bowel syndrome (IBS) comparing Mutaflor with Placebo (2 arms). Primary endpoint: Global improvement of IBS-related symptoms at 8 weeks. Started Oct 2006; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)Postinfectious irritable bowel syndrome (PI-IBS)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2006-000500-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000500-16.